Annexon股票討論區

$Annexon(ANNX.US)$
NEWS
Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting
Annexon, Inc. (Nasdaq: ANNX) will present data at the ARVO 2024 Annual Meeting showcasing the neuroprotective effects of ANX007 and C1q inhibition in Geographic Atrophy. The Phase 2 ARCHER trial results will be discussed, highlighting the protection of visual acuity and anatomical structure with ANX007 treatment. New preclinica...

$Travere Therapeutic(TVTX.US)$  Phase 3
$CG Oncology(CGON.US)$  Phase 3
$美國聯合醫療(UTHR.US)$  Phase 3
$美國聯合醫療(UTHR.US)$  Phase 3
$BioCardia(BCDA.US)$  Phase 3
$Insmed(INSM.US)$  Phase 3
$GlycoMimetics(GLYC.US)$  Phase 3
$Annexon(ANNX.US)$  Phase 3
$Lipocine(LPCN.US)$  Phase 3
$FibroGen(FGEN.US)$  Phase 3
$烏龍製藥(URGN.US)$  Phase 3
$Lyra Therapeutics(LYRA.US)$  Phase 3
$Citius Pharmaceuticals(CTXR.US)$  Phase 3
$Jaguar Health(JAGX.US)$  Phas...

The Wells Fargo equity team identified 14 high-conviction, catalyst-driven stock opportunities for the second quarter, including two Magnificent 7 names: Amazon and Tesla.
The list, updated each quarter, indicates where analysts "see significant Q2 24 catalysts that could drive meaningful upside or downside."
The list includes 10 Long (or Overweight) trades and 4 Short (or Underweight) trades:
$亞馬遜(AMZN.US)$ , $Annexon(ANNX.US)$ ,...

🎯 Ph 3 readouts in Q2 2024...
$Intra-Cellular Therapies(ITCI.US)$  Phase 3
$CG Oncology(CGON.US)$  Phase 3
$和黃醫藥(HCM.US)$  Phase 3
$Viracta Therapeutics(VIRX.US)$  Phase 3
$GlycoMimetics(GLYC.US)$  Phase 3
$Annexon(ANNX.US)$  Phase 3
$Lipocine(LPCN.US)$  Phase 3
$FibroGen(FGEN.US)$  Phase 3
$烏龍製藥(URGN.US)$  Phase 3
$Lyra Therapeutics(LYRA.US)$  Phase 3
$Citius Pharmaceuticals(CTXR.US)$  Phase 3
$Marinus Pharmaceuticals(MRNS.US)$  Phase 3
$BioCardia(BCDA.US)$  Phase 3...

$Annexon(ANNX.US)$ Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected in Second Quarter 2024
Initiation of Pivotal Phase 3 ANX007 ARCHER II Trial in Geographic Atrophy (GA) Expected in mid-2024, a Global Sham-Controlled Trial Using Vision Preservation as Primary Outcome Measure
Clinical Proof-of-Concept Data with ANX1502 Oral Inhibitor of the Classical Pathway Expected in Second Half of 2024

$輝瑞(PFE.US)$  Phase 2
$Leap Therapeutics(LPTX.US)$  Phase 2
$Vera Therapeutics(VERA.US)$  Phase 2b
$4D Molecular Therapeutics(FDMT.US)$  Phase 2
$Adverum Biotechnologies(ADVM.US)$  Phase 2
$Denali Therapeutics(DNLI.US)$  Phase 2
$Akero Therapeutics(AKRO.US)$  Phase 2b
$Spruce Biosciences(SPRB.US)$  Phase 2
$Xencor(XNCR.US)$  Phase 2
$阿里拉姆制藥(ALNY.US)$  Phase 2
$Harmony Biosciences(HRMY.US)$  Phase 2
$Annexon(ANNX.US)$  Phase 2a
$Roivant Sciences(ROIV.US)$...

$Annexon(ANNX.US)$ No Ôn Hailo, Low Wo, No ôn to loda, must Sell 👍😍

$Annexon(ANNX.US)$ why so low 🤔
so much for $16 target wtf 😭😳